John Crown Highlights Tebentafusp Milestone and Access Disparity in Uveal Melanoma
John Crown, Chair of Translational Cancer Medicine at Dublin City University, shared a post on X:
“Tebebtafusp is the 1st drug to show overall survival advantage in metastatic uveal (eye) melanoma.
We gave the first dose outside of compassionate access last week.
Sadly-now the latest example of 2Tier care. Not available in HSE.”
Patrick Forde, Professor at Johns Hopkins University and Co-Director of the Division of Upper Aerodigestive Malignancies at the Sidney Kimmel Comprehensive Cancer Center, reshared the shared a post on X, adding:
“As NI follows NHS England, several key cancer treatments are available in Derry but not in Donegal etc.
It’s a complex q but Ireland is near bottom of the table in treatment access.
The govt has expressed an interest in improving the situation.”
More posts featuring Patrick Forde.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023